About

We’ve reinvented how biologic drugs are invented

Lumen’s patented technology allows us to use the well-known food algae spirulina to deliver therapeutic proteins.

Patented technology with unlimited potential

The astonishingly high cost of traditional drug development meant that using orally delivered biologics to address therapeutic targets in the GI tract and other topical sites wasn’t commercially viable. That’s no longer true. Lumen’s patented biologic drug platform shortens the development process, reduces costs and risks, and accelerates time-to-market, making us the first company to make orally delivered antibody drugs commercially viable.

image not displayed used for development purposes

$65M

invested to date

23

issued patents

14

other patents pending

01

Formation

  • Incorporated April 2017

  • Foundational IP, core team, assets acquired from two predecessor entities

02

Funding

  • $65 million in platform investment to date

03

Intellectual Property

  • 23 issued patents 

  • Issued patents include broad, composition-of-matter claims covering engineered spirulina, recognition that Lumen was the first in the world to engineer spirulina

  • Broad continuation claims cover all long-term contemplated products

  • 14 other patents pending

 

04

Physical Capabilities

  • 50 FTEs, including >25 with MDs, PhDs, and other post-graduate degrees

  • Fully integrated, on-premise, dedicated cGMP production facility with capacity for several kilograms of drug product per week

  • Full-time clinical operations and FDA regulatory affairs team

  • High-throughput strain engineering facility

  • Advanced protein engineering and optimization

  • Large-scale AI/machine learning–enabled yield optimization facility

  • On-premise antibody selection and optimization capabilities (hit to the lead clinic), including advanced in silicoprotein engineering and optimization

hidden bg image

A typical biosciences company assembles a group of individuals with a relatively narrow set of skills within a discipline and goes about its business. At Lumen, it’s the particularity of our key scientists’ individual skills and experiences—and the interplay among them—that have been a catalyst to discover and exploit the potential of this new platform organism. As a true platform company, we’re able to create our own portfolio of commercially viable biologic therapies, while establishing a foundation upon which an entirely new generation of scientific discoveries and therapies will be brought to market.

The multidisciplinary expertise of our key people makes them literally one-of-a-kind, but the fact that they’re working together on the same team gives Lumen a nearly unprecedented strategic advantage.

Brian Finrow

CEO & Co-Founder

Expertise. Ingenuity. Execution.

We’ve assembled a talented group of leaders with deep expertise in synthetic biology, protein design, immunology, photobioreactor engineering and cell physiology, each with the vision and skills needed to achieve our mission.

Brian Finrow

Co-Founder and Chief Executive Officer

  • Adaptive Biotechnologies

  • AltAir Fuels

  • Cooley, LLP

  • Harvard Law School

Read Bio

Jim Roberts

Co-Founder and Chief Scientific Officer

  • Director, Fred Hutch Cancer Research Center, Basic Sciences Division

  • Former HHMI Investigator

  • Co-inventor of a mammalian cell

  • Transformation technology

Read Bio

Craig Behnke

SVP, Production/Development

  • Sapphire Energy

  • Takeda Pharmaceuticals

  • University of Washington, PhD, Biochemistry

Read Bio

Don Schlosser

CFO

  • Veteran VC-backed technology company CFO

  • Varolii Corp

  • King Broadcasting

  • Arthur D. Little

Read Bio

Michael Spigarelli

Chief Medical Officer

  • University of Utah, David Eccles School of Business, MBA

  • University of Michigan, Rackham Graduate School, PhD, Medicinal Chemistry

  • University of Michigan Medical School, MD

Read Bio
Lumen_Symbol-01

Barry Stoddard

  • Member, Fred Hutch Cancer Research Center, Basic Sciences Division

  • Structural biology and protein design

Richard Guerrant

  • Founding Director, Center for Global Health

  • Professor of International Medicine, University of Virginia, Division of Infectious Diseases and International Health

James Lord

  • Assistant Member, Benaroya Research Institute

  • Gastroenterology, University of Washington School of Medicine

George McDonald

  • Professor Emeritus, Fred Hutch Cancer Research Center, Clinical Research Division, Gastroenterology

  • Professor Emeritus, University of Washington Medical School

Jim Nataro

  • Professor and Chair, Pediatrics

  • University of Virginia School of Medicine 

Scott Hensley

  • Associate Professor of Microbiology Penn Institute for Immunology

  • University of Pennsylvania School of Medicine

Michael Dodds

  • Executive Director, Integrated Drug Development

  • Certara

Brian Finrow

CEO & Co-Founder, Lumen

Jim Roberts, MD, PhD

CSO & Co-Founder, Lumen

George Montgomery

WestRiver Management

Rob Carlson

Bioeconomy Capital

Mark Litton

Athira Pharma

Funding Organizations

Lumen’s technology presents a new way to target diseases that traditional biopharma technologies have failed to solve, so we are thankful for the significant funding support we have received from a range of private foundations, NGOs and government agencies.

Research Collaborators

In many cases the cutting edge of discovery is carried out at non-commercial research institutions like universities and government labs. We are honored to be working closely with so many researchers who are leaders in their respective fields.

image not displayed used for development purposes

Inspired by science. Driven by results.

We are always on the lookout for creative, motivated people who want to make a difference.

See open positions